Clinical Trials for Mesothelioma Patients: Novartis LBH589 Study Description
Read the study description for a current clinical trial being conducted to study the effects of Novartis LBH589 for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. For additional information, contact Novartis at 1-800-340-6843.
Study Description
Phase, Type and Design: Phase I Interventional Study; Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Primary Outcome Measure: Pharmacokinetic (PK) parameters Safety and tolerability (days 1-10) assessed by AEs, SAEs, labs, ECG reports, radiology reports.
Secondary Outcome Measure : Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs) Safety and tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation
Requisite Conditions: Carcinoma, Non-Small-Cell Lung Mesothelioma
Intervention: Drug: LBH 589Recruitment Information
Recruitment Status: Recruiting
Enrollment : 24
Start Date: September 2007
Courtesy of ClinicalTrials.gov.
Other helpful links:
Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney
Clinical trial to study Vitamin B12 outcome on mesothelioma patients